Shilpa Medicare Limited
SHILPAMEDPharmaceuticals
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics.
181Announcements
11-09-2026Last filed
27Last 90 days
What Shilpa files
- Important41
- Updates40
- Others36
- Investor Meet26
- Board Meeting14
- PPTs8
Showing New Orders announcements (1)Clear filter
11-09-2026 · 01:26 pm
Shilpa Medicare Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Shilpa Medicare's Novel Complex Injectable OERIS (Ondansetron Extended-Release Injection, 100 mg/mL) receives final approval from Subject Expert Committee (SEC) for grant of marketing authorization.".